N-lorem Foundation
Clinical trials sponsored by N-lorem Foundation, explained in plain language.
-
One-of-a-Kind drug created for single child in groundbreaking trial
Disease control OngoingThis study is testing a custom-made drug designed for a single child with a rare genetic disorder called NEDBA, which affects brain development and movement. The goal is to see if the treatment is safe and if it can help improve the child's motor skills, reduce seizures, and enha…
Phase: PHASE1, PHASE2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Apr 02, 2026 05:57 UTC
-
One-of-a-Kind genetic therapy trial launches for Ultra-Rare disorder
Disease control OngoingThis study is testing a custom-made genetic medicine for a single person with a rare developmental disorder called Bainbridge-Ropers syndrome. The goal is to see if the treatment is safe and if it can help improve the participant's motor skills, communication, and quality of life…
Phase: PHASE1, PHASE2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
One-of-a-Kind drug created for single Patient's rare disease
Disease control ENROLLING_BY_INVITATIONThis study is testing a custom-made drug designed specifically for one person with a rare, inherited nerve disorder called Charcot-Marie-Tooth disease type 2D. The drug aims to slow or stop the progression of the disease by targeting the patient's unique genetic mutation. Researc…
Phase: PHASE1, PHASE2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
One-of-a-Kind genetic drug trial launched for single Patient's rare eye disease
Disease control OngoingThis study is testing a personalized genetic drug designed for a single patient with a rare form of inherited retinal dystrophy. The goal is to see if the custom treatment is safe and if it can help slow or stop the progression of vision loss. Researchers will carefully monitor t…
Phase: PHASE1, PHASE2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Mar 16, 2026 15:27 UTC